Adjuvant use of multispecies probiotic in the treatment of peri‐implant mucositis: A randomized controlled trial

• Published in: Journal of clinical periodontology 2022-08, Vol.49 (8), p.828-839
• Main Authors: Santana, Sandro I., Silva, Pedro H. F., Salvador, Sérgio L., Casarin, Renato C. V., Furlaneto, Flávia A. C., Messora, Michel R.
• Format: Article
• Language: English
• Subjects: Bleeding; Clinical trials; dental implant; Dental implants; Edentulous; Immunology; Interleukin 6; Mucositis; Patients; Placebos; Plaque index; probiotic; Probiotics; Tumor necrosis factor; Tumor necrosis factor-TNF; Tumors
• ISSN: 0303-6979; 1600-051X
• DOI: 10.1111/jcpe.13663

Aim This randomized placebo‐controlled clinical trial evaluated the effects of multispecies probiotic containing Lactobacillus rhamnosus HN001™, Lactobacillus paracasei Lpc‐37®, and Bifidobacterium animalis subsp lactis HN019™ as an adjunct to mechanical debridement (MD) on changes in bleeding on probing (BOP) in edentulous patients with peri‐implant mucositis (PiM). Materials and Methods Patients were randomly assigned to test (probiotic) or control (placebo) groups. All sites with PiM received MD and topical gel application (probiotic or placebo) at baseline and 12 weeks. After initial MD, patients consumed probiotic or placebo capsules twice a day for 12 weeks. Clinical (modified sulcus bleeding index [mSBI]; modified plaque index [mPI]; probing depth [PD]; and BOP) and immunological parameters were collected at baseline and after 12 and 24 weeks. Data were statistically analysed (p